56 related articles for article (PubMed ID: 23146264)
1. Investigating the antitumor effects of a novel ruthenium (II) complex on malignant melanoma cells: An NMR-based metabolomic approach.
Hussan A; Moyo B; Amenuvor G; Meyer D; Sitole L
Biochem Biophys Res Commun; 2023 Dec; 686():149169. PubMed ID: 37922571
[TBL] [Abstract][Full Text] [Related]
2. Emerging Molecular Receptors for the Specific-Target Delivery of Ruthenium and Gold Complexes into Cancer Cells.
Machado JF; Correia JDG; Morais TS
Molecules; 2021 May; 26(11):. PubMed ID: 34070457
[TBL] [Abstract][Full Text] [Related]
3. Potent Ruthenium-Ferrocene Bimetallic Antitumor Antiangiogenic Agent That Circumvents Platinum Resistance: From Synthesis and Mechanistic Studies to
M M; Gadre S; Chhatar S; Chakraborty G; Ahmed N; Patra C; Patra M
J Med Chem; 2022 Dec; 65(24):16353-16371. PubMed ID: 36459415
[TBL] [Abstract][Full Text] [Related]
4. Dinuclear thiolato-bridged arene ruthenium complexes: from reaction conditions and mechanism to synthesis of new complexes.
Primasová H; Ninova S; de Capitani M; Daepp J; Aschauer U; Furrer J
RSC Adv; 2020 Nov; 10(66):40106-40116. PubMed ID: 35520857
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the Activities of Dinuclear Thiolato-Bridged Arene Ruthenium Complexes against Toxoplasma gondii.
Basto AP; Müller J; Rubbiani R; Stibal D; Giannini F; Süss-Fink G; Balmer V; Hemphill A; Gasser G; Furrer J
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652238
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.
Irace C; Misso G; Capuozzo A; Piccolo M; Riccardi C; Luchini A; Caraglia M; Paduano L; Montesarchio D; Santamaria R
Sci Rep; 2017 Mar; 7():45236. PubMed ID: 28349991
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in ruthenium anticancer drugs.
Levina A; Mitra A; Lay PA
Metallomics; 2009 Nov; 1(6):458-70. PubMed ID: 21305154
[TBL] [Abstract][Full Text] [Related]
8. Strained ruthenium complexes are potent light-activated anticancer agents.
Howerton BS; Heidary DK; Glazer EC
J Am Chem Soc; 2012 May; 134(20):8324-7. PubMed ID: 22553960
[TBL] [Abstract][Full Text] [Related]
9. New π-arene ruthenium(II) piano-stool complexes with nitrogen ligands.
Grau J; Noe V; Ciudad C; Prieto MJ; Font-Bardia M; Calvet T; Moreno V
J Inorg Biochem; 2012 Apr; 109():72-81. PubMed ID: 22387934
[TBL] [Abstract][Full Text] [Related]
10. Anticancer activity of opened arene ruthenium metalla-assemblies.
Barry NP; Zava O; Furrer J; Dyson PJ; Therrien B
Dalton Trans; 2010 Jun; 39(22):5272-7. PubMed ID: 20442944
[TBL] [Abstract][Full Text] [Related]
11. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
12. Insights into the mechanism of action and cellular targets of ruthenium complexes from NMR spectroscopy.
Giannini F; Paul LE; Furrer J
Chimia (Aarau); 2012; 66(10):775-80. PubMed ID: 23146264
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
